04:10 AM EST, 11/07/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said late Thursday it priced a private offering of $650 million of 0% convertible senior notes due 2031 and $650 million of 0.875% convertible senior notes due 2032.

Initial purchasers have a 13-day overallotment option to purchase up to $100 million of additional notes of each series.

Net proceeds, estimated to be $1.27 billion to $1.47 billion, will be used to fund certain capped call transactions, among other things, the company said.

Halozyme expects the offering to close Wednesday.